Neuropharmacology & Neurotherapeutics
Drug-induced cerebrovascular disease
Oct. 18, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
(Modified from: Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012;106(3):330-44. And Patterson MC, Clayton P, Gissen P, et al. Recommendations for the detection and diagnosis of Niemann-Pick disease type C. Neurol Clin Pract 2017;7(6):499-511.) Abbreviations: GD: Gaucher disease; ASM: acid sphingomyelinase; EM: electron microscopy; MLPA: Multiplex Ligation-dependent Probe Amplification. This technique evaluates copy number changes and has allowed detection of large deletions, so far only in the NPC1 gene. It has also been useful to detect a false homozygous status with a deletion on the other allele. (a) New test under clinical development, see text; (b) I-cell disease (ML-II and –III) gives a false positive result (but very different clinical features); (c) ASM deficiency can give a similar filipin pattern; (d) not certainly pathogenic; (e) DNA is usually needed to study the effect of splice mutations; (f) check allele segregation by parental study.